BioSpace News Archive

Braxia Scientific Corp. is pleased to announce positive preliminary results from the first Health Canada Approved, Phase II, randomized clinical trial to evaluate the feasibility, safety, tolerability, and efficacy of multi-dose psilocybin-assisted therapy for Treatment-Resistant-Depression.

Cardio Flow, Inc., a medical device company and developer of minimally invasive peripheral vascular devices to treat peripheral artery disease (PAD), today announced it recently received U.S. Food and Drug Administration (FDA) clearance for the company’s FreedomFlow® Peripheral Guidewire.

Recursion, the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced its participation in the following upcoming investor conferences:

Codex DNA, Inc., a pioneer in automated benchtop synthetic biology systems, announced that Todd R. Nelson, PhD, the company’s chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Friday, June 10th at 9:00 am Eastern time / 6:00 am Pacific Time.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies Healthcare Conference in New York, NY. Members from the management team are scheduled to participate in a fireside chat on Thursday, June 9, 2022 at 10:30 a.m. ET.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis, announced its management team will participate in three upcoming investor conferences.

Gritstone bio, Inc., a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, announced that the company has been certified as a Great Place to Work by the Great Place to Work® Institute.

TRACON Pharmaceuticals announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 11:00 am Eastern Time.

Aerovate Therapeutics, Inc. announced that Company management will present at the Jefferies Global Healthcare Conference on Thursday, June 9, at 3:30 p.m. ET, including an overview of AV-101 and the IMPAHCT Phase 2b/Phase 3 trial.

Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will participate in a “Fireside Chat” presentation at the Jefferies Healthcare Conference, to take place June 8-10, 2022, in New York, NY.